Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3261-3269

  Bertilsson, Helena ^a,b   Tessem, May Britt ^a   Flatberg, Arnar ^a   Viset, Trond ^b   Gribbestad, Ingrid ^a   Angelsen, Anders ^b   Halgunset, Jostein ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; CHOLINE; CHOLINE KINASE; CHOLINE KINASE ALPHA; CITRIC ACID; ISOCITRATE LYASE; PHOSPHOLIPASE A2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RNA EXTRACTION; TRANSCRIPTOMICS; TUMOR VOLUME;

ACONITATE HYDRATASE; ATP CITRATE (PRO-S)-LYASE; CHOLINE; CHOLINE KINASE; CITRIC ACID; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A2; PROSTATE; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84862534252     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2929     Document Type: Article

References (33)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646 -74.
2. Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res 2004;70:6692-6.
3. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging 2011;33:258-74.
4. Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59:962-77.
5. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451-63. (Pubitemid 35167879)
6. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, et al. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol 2011;60:1074-80.
7. Moestue S, Sitter B, Bathen TF, Tessem MB, Gribbestad IS. HR MAS MR spectroscopy in metabolic characterization of cancer. Curr Top Med Chem 2011;11:2-26.
8. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4. (Pubitemid 29062961)
9. Glunde K, Jiang L, Moestue SA, Gribbestad IS. MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed 2011; 24:673- 90.
10. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-603. (Pubitemid 32694969)
11. Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, Raman V, et al. Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res 2009;69:3464-71.
12. Costello LC, Franklin RB, Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 1999;38:237-45. (Pubitemid 29054940)
13. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006;5:17.
14. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005;8:311-21. (Pubitemid 41443416)
15. Zadra G, Priolo C, Patnaik A, Loda M. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 2010;16:3322-8.
16. Bertilsson H, Angelsen A, Viset T, Skogseth H, Tessem MB, Halgunset J. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy. Prostate 2011;71:461- 9.
17. Hansen KD, Irizarry RA, Wu Z. Removing technical variability in RNAseq data using conditional quantile normalization. Biostatistics 2012;13:204-16.
18. Costello LC, Franklin RB. Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution! Mol Cancer 2006;5:59.
19. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011;223:283-94.
20. Costello LC, Franklin RB. Integration of molecular genetics and proteomics with cell metabolism: how to proceed; how not to proceed! Gene 2011;15:88-93.
21. Singh KK, Desouki MM, Franklin RB, Costello LC. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer 2006;5:14.
22. Hanai JI, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways. J Cell Physiol 2012;227:1709-20.
23. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008;68:8547-54.
24. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009;12:259-63.
25. Capitanio U, Suardi N, Briganti A, Gallina A, Abdollah F, Lughezzani G, et al. Influence of obesity on tumour volume in patients with prostate cancer. BJU Int 2012;109:678-84.
26. Patel MI, Kurek C, Dong Q. The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 2008;179:1668- 75.
27. Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol 2011;178:525-36.
28. Lenkinski RE, Bloch BN, Liu F, Frangioni JV, Perner S, Rubin MA, et al. An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. MAGMA 2008;21:411-21.
29. Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramirez de Molina A, Lacal JC, et al. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 2010;70:5507-17.
30. Teahan O, Bevan CL, Waxman J, Keun HC. Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol 2011;43:1002-9.
31. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-14. (Pubitemid 40250824)
32. vanAsten JJ, Cuijpers V, Hulsbergen-vandeKaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, et al. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA 2008;21:435-42.
33. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-7.